Review Article
Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective
Table 2
In vitro studies of herbs in the application of DCM.
| Drug | Dosage | Experimental model | Reference |
| Triptolide | 20 ng/ml | High-glucose cultured H9c2 rat cardiac cells | [64] | C66 | 2.5, 5, or 10 μmol/L | High-glucose cultured H9c2 cells | [69] | C66 | 2.5, 5, or 10 μmol/L | High-glucose cultured neonatal rat cardiomyocytes | [69] | Resveratrol | 50 μM | High-glucose cultured neonatal rat cardiomyocytes | [79] | Astragalus polysaccharides | 0.8 mg/ml | High-glucose cultured H9c2 cardiomyocytes | [85] | Myricitrin | 25 μg/ml | AGE-induced H9c2 cells | [90] | Taxifolin | 20, 40 μg/ml | High-glucose cultured H9c2 cells | [92] | Naringin | 80 μM | High-glucose cultured H9c2 cells | [96] | Total saponins of Aralia taibaiensis | 25, 50, and 75 μg/ml | G/GO cultured H9c2 cardiomyocytes | [109] |
|
|
C66; Compound (2E, 6E)-2,6-bis (2-(trifluoromethyl)benzylidene) cyclohexanone; AGE: advanced glycation end products; G/GO: 33 mM glucose + 15 mU glucose oxidase.
|